News

Catch up on coverage from the 22nd annual Society of Dermatology Physician Associates Fall Dermatology Conference in Las Vegas, Nevada.

The JAK inhibitor was significantly superior in all safety and efficacy endpoints, when compared to other AA treatment options.

Researchers recommend limiting routine lipase tests to symptomatic patients or those with radiographic signs of pancreatic injury.

Certain factors may contribute to higher occurrences of non-melanoma skin cancer in these patients, according to a novel systemic review.

According to the company, comparative tests revealed PN-881 surpasses or matches the efficacy of current injectable IL-17 therapies.

Researchers found the TYK2 inhibitor deucravacitinib offers superior efficacy to apremilast and comparable outcomes to biologics.

Review insights from a premier dermatology event with expert sessions, hands-on insights, and networking to elevate clinical practice.

The LIBERO study confirmed brodalumab is effective in managing psoriasis in patients over 100 kg, showing comparable long-term benefits in patients under 100 kg.

Christopher Bunick, MD, PhD, discusses the multifactorial nature of chronic hand eczema, the burden of severe symptoms, and how delgocitinib restores skin integrity by targeting JAK/STAT pathways.

These findings further suggest the implications of acne vulgaris treatment on the skin barrier.

Andrea Rosik, MS, PA-C, provides insights into managing challenging cases of atopic dermatitis.

Pediatric melanoma, though rare, is the deadliest skin cancer in children, with 300-500 US cases annually.

The novel clinical trial compared the AAK cream to triple combination cream in treating patients with melasma.

The study underscores the need for careful dietary advice to balance effective AD management and minimize food allergy risks.

Patients achieved excellent new hair growth and strength when combining PRP with drug therapy after hair transplantation surgery.

The study is set to begin enrollment later this year.

VSLS laser technology offers safe, effective treatment for solar lentigines, minimizing PIH and recurrence with advanced cooling and precision targeting.

Australian researchers found 5-FU to be the cheapest AK treatment, compared to imiquimod and MAL-photodynamic therapy.

A novel study assessed the potential of 2 AI platforms in providing accurate information to patients with HS.

Research suggested acne is primarily inflammatory, occurring even in unaffected skin, redefining its pathophysiology.

ENS-002 targets S. aureus in atopic dermatitis.

The drug is the first FDA-approved treatment for moderate to severe HS that selectively inhibits both IL-17A and IL-17F.

Benjamin Lockshin, MD, FAAD, discussed combining biologics with topical innovations like tapinarof and roflumilast to address plaque psoriasis treatment gaps.

The company’s phase 3 trials show JNJ-2113 significantly improves skin clearance and tolerability for patients with moderate to severe psoriasis.

Patients with moderate to severe atopic dermatitis saw the most improvement after taking 600 mg of tozorakimab.

Patients treated with dupilumab saw substantial healing, with over 70% achieving >50% lesion improvement in 24 weeks.

2-year data show 75.7% of TNFi-IR patients maintained ACR50, 80.6% achieved PASI100, and pain and fatigue improvements were sustained.

November's cover feature highlights the revolutionary role of artificial intelligence in the development of zasocitinib for the treatment of psoriasis.

A recent analysis found primary closure in HS surgery has higher recurrence rates, while secondary intention healing avoids complications but prolongs recovery.

Higher stress hyperglycemia ratios are linked to elevated mortality risk in psoriasis, highlighting its systemic nature and need for intensive care.